New chemical and biological entities approved by the Therapeutic Goods Administration, January 1, 2005 to May 7, 2024
| Field | Value | Language |
| dc.contributor.author | Lexchin, Joel | |
| dc.contributor.author | Hooimeyer, Ashleigh | |
| dc.coverage.spatial | Australia | en_AU |
| dc.coverage.temporal | 2005-2024 | en_AU |
| dc.date.accessioned | 2024-12-02T02:36:10Z | |
| dc.date.available | 2024-12-02T02:36:10Z | |
| dc.date.issued | 2024-12-02 | |
| dc.identifier.uri | https://hdl.handle.net/2123/33346 | |
| dc.description.abstract | This dataset includes information on drug approvals by the Australian Therapeutic Goods Administration (TGA) from 2005 to May 2024. Generic, brand name, indication, approval pathway (when applicable), and date of approval are included. In addition, therapeutic ratings from the Patented Medicines Prices Review Board (PMPRB, Canada), Prescrire, Haute Autorité de Santé (HAS, France), and the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG, Germany), and Pharmaceutical Benefits Schedule (PBS) listing status have been included. | en_AU |
| dc.language.iso | en | en_AU |
| dc.rights | Creative Commons Attribution-NonCommercial 4.0 | en_AU |
| dc.subject | pharmaceutical regulation | en_AU |
| dc.subject | TGA | en_AU |
| dc.subject | Prescrire | en_AU |
| dc.subject | IQWIG | en_AU |
| dc.subject | PMPRB | en_AU |
| dc.subject | PBS | en_AU |
| dc.title | New chemical and biological entities approved by the Therapeutic Goods Administration, January 1, 2005 to May 7, 2024 | en_AU |
| dc.type | Dataset | en_AU |
| dc.subject.asrc | ANZSRC FoR code::32 BIOMEDICAL AND CLINICAL SCIENCES::3214 Pharmacology and pharmaceutical sciences::321402 Clinical pharmacology and therapeutics | en_AU |
| dc.identifier.doi | 10.25910/ttz0-rf81 | |
| dc.description.method | The information in the database come from a variety of organisational databases. The methods are provided in more detail in Lexchin 2022 and the included README file. Lexchin J. Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study. Aust Health Rev. 2022;46(3):309-315. | en_AU |
| usyd.faculty | Faculty of Health, School of Health Policy and Management, York University | en_AU |
| usyd.faculty | Faculty of Medicine and Health, School of Pharmacy, the University of Sydney | en_AU |
| workflow.metadata.only | No | en_AU |
Associated file/s
Associated collections